|
Upcoming trials
-
Safety, tolerability,
and neuroprotection of atacicpet assessed by optical coherence
tomography (OCT) in optic neuritis as clinically isolated syndrome
(CIS)
-
Efficacy and safety
of NG 00012 (dimethyl fumarate) in relapsing remitting MS, using
glatiramer acetate as active reference.
-
Efficacy and safety
of two different doses of teriflunamide in patients with
relapsing-remitting MS using interferon beta 1a subcutaneous as a
calibrator.
-
Two annual cycles of
intravenous low and high dose alemtuzumab compared to three-times
weekly subcutaneous interferon beta 1a.
Publications and
abstracts
Safety and immunogenicity
of interferon beta 1a in a phase IIIb study in patients with relapsing
MS: 48 week results. Multiple Sclerosis. 13: S53, 2007
Impact of oral
antihistamine on local injection site reactions with glatiramer acetate.
Multiple Sclerosis. 13: S134, 2007
Rebif New Formulation (RNF;
interferon beta 1-a): 1-year results of a phase IIIb study in patients
with relapsing forms of multiple sclerosis. Journal of Neurology.
254(S3): 15, 2007
Immunogenicity and
tolerability of Interferon Beta 1a (Rebif New Formulation): 24 and 48
week interim analyses of 2-year, open-label, historically controlled,
Phase IIIb study in adults with Multiple Sclerosis. Clinical
Therapeutics. 29(6): 1128-1145, 2007.
Safety and immunogenicity
of Rebif New Formulation (RNF) a new subcutaneous formulation of
interferon beta-1a 44 mcg three times weekly: 1-year results of a phase
IIIb study in patients with relapsing multiple sclerosis. Neurology. 68
(12) S1: A274, March 2007.
Reduced immunogenicity
with a new formulation of interferon beta 1a (Rebif): 24-week results of
a phase IIIb study. Multiple Sclerosis. 12: S192, 2006.
A study model to
investigate adherence to treatment among patients with
relapsing-remitting multiple sclerosis initiating therapy with
glatiramer acetate via pre-filled syringe. Multiple Sclerosis. 11(S1):
s83, 2005
The role of self-efficacy
in predicting adherence to glatiramer acetate in pre-filled syringes
among patients with and without prior treatment experience with
immunomodulatory therapy. Multiple Sclerosis. 11(S1): S83, 2005.
Predicting adherence to
therapy with glatiramer acetate administered with pre-filled syringes in
patients with relapsing-remitting multiple sclerosis. Multiple
Sclerosis. 11(S1): S83, 2005.
Multiple Sclerosis and
Optic Neuritis. Focal Points. American Academy of Ophthalmology. 2004.
|
